Ireland passes bill to encourage generics use

Home/Policies & Legislation | Posted 31/05/2013 post-comment0 Post your comment

On 22 May 2013, the Health (Pricing and Supply of Medical Goods) Bill 2012 was passed by both Houses of the Oireachtas (Irish Parliament).

picture 80

The Bill aims to encourage the use of generics by establishing a list of groups of drugs which may be substituted for each other in order to enable savings to be made for patients and the Irish Health Service Executive (HSE). The Bill also aims to establish mechanisms to set the prices of such drugs via introduction of a reference pricing system.

At present, pharmacists in Ireland may not substitute a generic for a brand-name medicine, if a specific brand-name drug is prescribed for a patient, even if a lower cost generic drug is available.

Minister for Health Dr James Reilly said ‘this legislation gives effect to the commitment in the Programme for Government that reference pricing and greater use of generics would be introduced to reduce the State’s large drug bill and the cost to individuals of their medicines. It will promote price competition and deliver lower medicine prices for both the State and patients.’

Minister for Health Mr Alex White added that ‘the Bill permits pharmacists to substitute medicines which have been designated as interchangeable by the Irish Medicines Board (IMB). It is only where the IMB is satisfied that a medicinal product satisfies all the conditions set out in the Bill that it can do so. To further enhance patient safety, the Bill allows a prescriber to indicate on a prescription that a branded interchangeable medicinal product should, for clinical reasons, not be substituted.’

Eligible patients will not face any additional costs for medicines priced at or below the reference price. If a patient wants to have a particular brand-name drug that costs more than the reference price then the patient will have to pay the additional cost of that product.

The Bill will now be referred to the Irish President for signature and is expected to come into effect in June 2013.

Related articles

Cost savings from use of generic medicines in Ireland

Use of generic medicines in Ireland

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2013 Pro Pharma Communications International. All Rights Reserved.

Source: DOH, Oireachtas

comment icon Comments (0)
Post your comment
Related content
USA BIOSIM Act introduction
02 AA010638
Home/Policies & Legislation Posted 17/09/2021
MERCOSUR: new tariff for biological and biosimilar without Latin equity
138 AA011155
Home/Policies & Legislation Posted 03/09/2021
New trade agreement between Mexico, the US and Canada
62 MD001919
Home/Policies & Legislation Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010